Response rates to first-line treatment in eligible patients to autologous stem transplantation in Chile

Vista sencilla de ítem
dc.contributor.authorRojas-Vallejos, Jorge
dc.contributor.authorEspinoza, Marcela
dc.contributor.authorDonoso, Javiera
dc.contributor.authorSoto, Pablo
dc.contributor.authorCardemil, Daniela
dc.contributor.authorPeña, Camila
dc.contributor.authorAranda, Sandra
dc.contributor.authorContreras, Carolina
dc.contributor.authorVergara, Carmen Gloria
dc.contributor.authorRocca, Gabriel
dc.contributor.authorOsorio, Rocío
dc.contributor.authorLópez-Vidal, Hernán
dc.date.accessioned2023-03-27T15:09:02Z
dc.date.available2023-03-27T15:09:02Z
dc.date.issued2019
dc.descriptionIndexación Scopuses
dc.description.abstractBackground: The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim: To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting. Material and Methods: Data from patients considered as candidates for HSCT from different centers of the National Adult Antineoplastic Drug Program (PANDA, for its acronym in Spanish), diagnosed between 2013 and 2017, was analyzed. The response to treatment of first and second lines of treatment was evaluated, in addition to the results of HSCT. An optimal Response was defined as the sum of strict complete remission, complete remission and very good partial response (sCR, CR and VGPR). Results: One hundred and seventy-seven patients were analyzed, 54% women, and 53% with IgG multiple myeloma. Information about the international staging system was retrieved in 127 patients (71%). Seventeen percent were ISS I, 22% in ISS II and 32% ISS III. CTD was used as first treatment in 106 patients (60%), and cyclophosphamide, bortezomib and dexamethasone (CyBorD) in 13 (7%). As first line, CTD had an overall response of 50.9%, and CyBorD of 76.9%. Thirty patients were treated with bortezomib as second line treatment. Forty patients (22%) underwent HSCT. The 5-year Overall Survival (OS) in transplanted patients and non-transplanted patients was 100 and 62% respectively (p < 0.01). Conclusions: The response rate achieved by CTD in these patients is suboptimal. The response to CyBorD was better.es
dc.identifier.citationRevista Medica de Chile Volume 147, Issue 12, Pages 1561 - 15682019es
dc.identifier.doi10.4067/S0034-98872019001201561es
dc.identifier.issn0034-9887
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/47899
dc.language.isoenes
dc.publisherRevista Medica de Chilees
dc.subjectBortezomibes
dc.subjectDexamethasonees
dc.subjectHematopoietic Stem Cell Transplantationes
dc.subjectMultiple Myelomaes
dc.titleResponse rates to first-line treatment in eligible patients to autologous stem transplantation in Chilees
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Response-rates-to-firstline-treatment-in-eligible-patients-to-autologous-stem-transplantation-in-ChileRevista-Medica-de-Chile.pdf
Tamaño:
700.56 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FEN - Artículos de Revista